Iovance IOVA 深 沪
交易中 05-11 11:03:26 美东时间
3.8002
+0.180
+4.98%
华盛通- 最 高4.15
- 今 开3.64
- 成交量 2530.93万股
- 最 低 3.38
- 昨 收 3.62
- 总市值 59.66万
- 52周最高 5.63
- 市盈率 静 --
- 换手率 16120.55%
- 52周最低 1.6385
- 委 比 11.12%
- 总股本 0.00亿
- 历史最高 54.208
- 量 比 5.87
- 振 幅 21.27%
- 历史最低 1.10
- 每 手 1
- 风险率 0.71%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Earnings Outlook For ARS Pharmaceuticals
ARS Pharmaceuticals (NASDAQ:SPRY) is set to give its latest quarterly earnings ...
2025-11-08 02:04
Earnings Scheduled For November 6, 2025
Companies Reporting Before The Bell • Clear Channel Outdoor (NYSE:CCO) is expec...
2025-11-06 19:12
盘前异动｜英特尔涨超6%，AEye涨超15%，Iovance飙升20%，Palo Alto Networks绩后涨超5%
8月19日，美股三大股指期货下跌，截止发稿，道指期货跌0.10%，纳指期货跌0.09%，标普500指数期货跌0.12%。 英特尔盘前涨超6%，软银集团与...
2025-08-19 16:06
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
Iovance Biotherapeutics授予58名新员工312,660股股票期权，行权价1.98美元，期权在三年内vest。
2025-06-23 20:05
Iovance Biotherapeutics to Present at Upcoming Conference
Iovance Biotherapeutics' senior leadership will participate in a fireside chat at the Goldman Sachs Global Healthcare Conference on June 11, 2025 at 1:20 p.m. ET in Miami, FL. The company focuses on developing polyclonal tumor infiltrating lymphocyte (TIL) therapies for cancer patients, with Amtagvi® being the first FDA-approved T cell therapy for solid tumors.
2025-06-10 12:45
Iovance Announces Five-year Results of Amtagvi® (lifileucel) in Patients with Advanced Melanoma at ASCO Annual Meeting
Iovance Biotherapeutics reported five-year results from its Phase 2 trial of Amtagvi, a TIL therapy for advanced melanoma. The study showed a median overall survival of 13.9 months, 19.7% five-year survival rate, and 31.4% objective response rate. No new adverse events were reported. Amtagvi is the first one-time cell therapy for solid tumors.
2025-05-22 21:31
吊打半导体新能源车，CGT即将来临，堪称人类有史以来最大的风口
2025年02月22日 00:30:45 “这是价值事务所的第1792篇原创文章” 很多朋友可能不太清楚，医药行业当下其实正处在一个全新时代的边缘，真的就是边缘...
2025-02-22 00:30
AST SpaceMobile And Polestar Automotive Are Among Top 10 Best Performing Mid-Cap Stocks in August: Are The Others In Your Portfolio?
The top 10 mid-cap stocks in August: Polestar Automotive, Upstart, Lumen Technologies, GDS Holdings, Tempus AI, Clear Secure, Iovance Biotherapeutics, Evolent Health, Semtech Corp, AST SpaceMobile.
2024-09-09 02:09
(IOVA) - Analyzing Iovance Biotherapeutics's Short Interest
Iovance Biotherapeutics's (NYSE:IOVA) short percent of float has fallen 3.22% since its last report. The company recently reported that it has 59.33 million shares sold short, which is 21.62% of all regular shares that are available for trading. Based on its trading volume, it would take traders 6.6...
2024-09-03 22:15
Watching Shares Of Iovance Biotherapeutics; Martin Shkreli Post On X, "$IOVA pretty attractive long idea"
https://x.com/MartinShkreli/status/1826325256434315536
2024-08-22 02:32
